Absence of relevant QT interval prolongation in not critically ill COVID-19 patients. 2020

Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
Cardiology Department, Virgen de Las Nieves University Hospital, Avenida de las fuerzas armadas 2, 18014, Granada, Spain. jimenez.jaimez@gmail.com.

SARS-CoV-2 is a rapidly evolving pandemic causing great morbimortality. Medical therapy with hydroxicloroquine, azitromycin and protease inhibitors is being empirically used, with reported data of QTc interval prolongation. Our aim is to assess QT interval behaviour in a not critically ill and not monitored cohort of patients. We evaluated admitted and ambulatory patients with COVID-19 patients with 12 lead electrocardiogram at 48 h after treatment initiation. Other clinical and analytical variables were collected. Statistical analysis was performed to assess the magnitude of the QT interval prolongation under treatment and to identify clinical, analytical and electrocardiographic risk markers of QT prolongation independent predictors. We included 219 patients (mean age of 63.6 ± 17.4 years, 48.9% were women and 16.4% were outpatients. The median baseline QTc was 416 ms (IQR 404-433), and after treatment QTc was prolonged to 423 ms (405-438) (P < 0.001), with an average increase of 1.8%. Most of the patients presented a normal QTc under treatment, with only 31 cases (14.1%) showing a QTc interval > 460 ms, and just one case with QTc > 500 ms. Advanced age, longer QTc basal at the basal ECG and lower potassium levels were independent predictors of QTc interval prolongation. Ambulatory and not critically ill patients with COVID-19 treated with hydroxychloroquine, azithromycin and/or antiretrovirals develop a significant, but not relevant, QT interval prolongation.

UI MeSH Term Description Entries
D008133 Long QT Syndrome A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME. Electrocardiogram QT Prolonged
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006886 Hydroxychloroquine A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) Hydroxychlorochin,Oxychlorochin,Oxychloroquine,Hydroxychloroquine Sulfate,Hydroxychloroquine Sulfate (1:1) Salt,Plaquenil

Related Publications

Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
January 2023, Cardiovascular drugs and therapy,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
August 2021, Cardiology research,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
January 2022, Journal of cardiovascular pharmacology and therapeutics,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
November 2021, American journal of critical care : an official publication, American Association of Critical-Care Nurses,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
October 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
December 2001, Journal of clinical pharmacology,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
October 2008, Pharmacoepidemiology and drug safety,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
August 2020, Kardiologiia,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
March 2021, JAMA cardiology,
Juan Jiménez-Jáimez, and Rosa Macías-Ruiz, and Francisco Bermúdez-Jiménez, and Ricardo Rubini-Costa, and Jessica Ramírez-Taboada, and Paula Isabel García Flores, and Laura Gallo-Padilla, and Juan Diego Mediavilla García, and Concepción Morales García, and Sara Moreno Suárez, and Celia Fignani Molina, and Miguel Álvarez López, and Luis Tercedor
March 2021, JAMA cardiology,
Copied contents to your clipboard!